Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Infusion Daunorubicin and Cytarabine for Older Patients with Untreated AML
NCT00023777Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2001
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daunorubicin and cytarabine in acute myeloid leukemia (AML), sponsored by SWOG Cancer Research Network. Primary endpoint: Complete Remission. Started Aug 2001; status: completed.
02
Drugs
daunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00023777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023777.